Well, I didn’t have that one on my bingo card. The market capitalization for drug maker Eli Lilly (LLY) crossed $1 trillion.
This is quite a feat, considering that the trillion-dollar club tends to be exclusively for tech stocks. But in developing and marketing drugs for obesity (Zepbound) and diabetes (Mounjaro) the past few years, it can be said that LLY’s own technology in the lab allowed it to break through.
